AtriCure Inc. (OQ:ATRC)

Business Focus: Medical Equipment, Supplies & Distribution

Sector:  Healthcare Industry:  Medical Equipment, Supplies & Distribution
 
See Regulatory Filings on SEC
Company Contact
Address: 7555 Innovation Way
MASON OH 45040-9695
Tel: N/A
Website: https://www.atricure.com
IR: See website
<
Key People
Scott William Drake
Independent Chairman of the Board
Michael H. Carrel
President, Chief Executive Officer, Director
Andrew Wade
Chief Financial Officer, Senior Vice President
Douglas J. Seith
Chief Operating Officer
Justin J. Noznesky
Senior Vice President, Marketing and Business Development
Salvatore Privitera
Chief Technology Officer
Business Overview
AtriCure, Inc. is an atrial fibrillation (Afib) solutions company. The Company develops, manufactures, and sells devices designed primarily for the surgical ablation of cardiac tissue and systems designed for the exclusion of the left atrial appendage. It has various product lines for the ablation of cardiac tissue, including its Isolator Synergy Ablation System, for the treatment of persistent and longstanding persistent forms of Afib in patients undergoing certain open concomitant procedures. It has two primary product lines for cardiac tissue ablation, which include Radio Frequency Ablation Devices and cryoICE Cryoablation System, and a product line for left atrial appendage exclusion. The Company also sells Lumitip dissectors and the Estech line of reusable cardiac surgery (valve) instruments. Its cryoICE cryosurgery product line offers various cryoablation devices. Its AtriClip Left Atrial Appendage Exclusion System is designed to occlude the heart's left atrial appendage (LAA).
Financial Overview
For the fiscal year ended 31 December 2019, AtriCure Inc. revenues increased 14% to $230.8M. Net loss before extraordinary items increased 58% to $35.2M. Revenues reflect Appendage Management segment increase of 29% to $68.2M, Open-Heart Ablation segment increase of 11% to $80.2M, United States segment increase of 15% to $185.8M, Asia segment increase of 26% to $16M. Higher net loss reflects Selling.
Employees: 730 as of Jan 31, 2020
Reporting Currency: U.S. Dollars
Enterprise value: $1,217M as of Dec 31, 2019
Annual revenue (TTM): $230.81M as of Dec 31, 2019
EBITDA (TTM): -$20.60M as of Dec 31, 2019
Net annual income (TTM): -$35.19M as of Dec 31, 2019
Free cash flow (TTM): -$27.99M as of Dec 31, 2019
Net Debt Last Fiscal Year: N/A
Shares outstanding: 40,048,972 as of Feb 20, 2020
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization